Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 1/20 | 0.31 |
| ▸ | GRM6 | O15303 | 2/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.31 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25475568 | 0.81 | APLNR (0.31) | APLNR | |
| SCHEMBL23904378 | 0.77 | CYP2C19 (0.34) | CYP1A2 | |
| SCHEMBL20182831 | 0.77 | APLNR (0.33) | APLNR | |
| SCHEMBL1468175 | 0.74 | — | — | |
| SCHEMBL19360778 | 0.73 | LMNA (0.35) | — | |
| SCHEMBL2300431 | 0.70 | FFAR3 (0.38) | — | |
| SCHEMBL5634851 | 0.70 | — | — | |
| SCHEMBL1661518 | 0.69 | APLNR (0.36) | APLNRGRM6GRM2GRM3CYP1A2 | |
| SCHEMBL19233 | 0.68 | CYP2C19 (0.38) | CYP1A2 | |
| Hydrochloric Acid SCHEMBL11387822 | 0.68 | FFAR3 (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | VERTEX PHARMACEUTICALS INCORPORATED | 2023-05-25 | — | — | US | disclosed |
| US-20170267661-A1 | INHIBITORS OF RET | BLUEPRINT MEDICINES CORPORATION | 2017-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230159521-A1 | 1H-PYRAZOLO[4,3-G]ISOQUINOLINE AND 1H-PYRAZOLO[4,3-G]QUINOLINE DERIVATIVES AS ALPHA-1-ANTITRYPSIN MODULATORS FOR TREATING ALPHA-1-ANTITRYPSIN DEFICIENCY (AATD) | SERPINA2, SERPINE1, SERPINA3 | APLNR 3152/4885GRM6 4519/4885GRM2 3903/4885 |
| US-20170267661-A1 | INHIBITORS OF RET | RET, HRAS, RB1 | APLNR 939/4885GRM6 1334/4885GRM2 1161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.